Galway, Ireland - The world’s first Clot Summit was held in Heidelberg, Germany, last week, chaired by Werner Hacke, MD, PhD, senior professor of Neurology at the University of Heidelberg Medical School, an eminent leader in the field of stroke.
The meeting was attended by internationally renowned clinicians from 12 countries, including many who played leadership roles in the recent positive clinical trials for endovascular stroke therapy, together with engineers and scientists focused on various areas of research in clot and acute stroke. The purpose of the multidisciplinary gathering was to identify ways to further advance the field of stroke therapy and improve patient care, with a focus on the main culprit in ischemic stroke – the clot that causes the occlusion. The summit’s design emphasized collaboration and cross-fertilization of ideas from clinicians, academics and engineers.
“This gathering of experts provided a valuable exchange of ideas and knowledge, and I am grateful for the opportunity to learn from respected colleagues in the field,” Prof. Hacke said. “The summit was well received, with attendees expressing interest in further interdisciplinary research on clot to improve stroke intervention and patient outcomes.”
During the summit, Neuravi presented insights gained from five years of the company’s pioneering research on the mechanical characteristics of clot and acute stroke occlusion dynamics.
“Understanding the science of occlusions is fundamental to Neuravi’s interest in advancing stroke therapy, and having the opportunity to collaborate with a diverse group of experts greatly enriches the process of discovery and learning. We are delighted with the success of the inaugural Clot Summit,” said Eamon Brady, CEO of Neuravi. “Through the Neuravi Thromboembolic Initiative (NTI), we will continue to pursue research, facilitate discussions, and build collaborations to deepen the understanding of the role of clot in acute stroke.”
“Thrombectomy has been proven as the best treatment for large vessel occlusive stroke, and now it is time to better understand clot in order to further advance care. This summit has contributed greatly to that discussion,” said Diederik Dippel, MD, PhD, senior consultant in the Department of Neurology at the Erasmus Medical Center in Rotterdam, the Netherlands and lead investigator of the MR CLEAN trial.
Raul Nogueira, MD, director of Neuroendovascular Service and Neurocritical Care at Grady Memorial Hospital in Atlanta, Georgia, also recognized the need for better clot science. “It is up to us to continue to push the envelope to further improve stroke care so that even more patients will benefit. I strongly believe that one of the best ways to do this is to build a better understanding of clot and occlusions.”
Based in Galway, Ireland, Neuravi is dedicated to improving clinical outcomes for stroke patients. The company’s initial stroke therapy platform, the EmboTrap Revascularization Device, is CE marked and commercially available in Europe. The device is available for investigational use only in the United States. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke. Neuravi is led by a team experienced in endovascular device development and global commercialization. More information can be found at www.neuravi.com.